Revenue (Tables)

9 Months Ended

Sep. 30, 2026

Revenue from Contract with Customer [Abstract]

The following table summarizes the changes in deferred revenue (in millions):


Deferred revenue at December 31, 20251	$	(56.3)
Additions related to development cost reimbursement received	(20.0)
Additions due to milestone achieved related to FDA approval	(100.0)
Recognized in revenue during the nine months ended September 30, 2026	187.7
Contract asset at September 30, 2026 (1)	$	11.4

(1) During the nine months ended September 30, 2026, the Company recognized $187.7 million of revenue and a contract asset of $11.4 million which the Company expects to bill in future periods as the contractual right to payment for collaboration services under the Exact Sciences License Agreement has not yet been raised. The contract asset was included as part of prepaid and other current assets on the condensed consolidated balance sheet. As of September 30, 2026, there was no deferred revenue under the agreement.

Schedule of Disaggregation of Revenue

The following table summarizes service and other revenue by type (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue type	2026		2025		2026		2025
Diagnostic and research services	$	—	$	0.3	$	—	$	0.3
EarlyCDT Lung royalties	0.5		0.3		1.3		0.7
EarlyCDT Lung test kits	0.3		0.3		0.8		1.1
EarlyCDT Lung test plates	0.1		0.1		0.2		0.4
Total revenue	$	0.9	$	1.0	$	2.3	$	2.5